Mesothelioma Web logo




Veterans Resources

Firefighters and Asbestos


  1. Par unit buys licensing rights for malignant mesothelioma drug from
    Alfacell will retain the right to co-promote Onconase in the future and is also entitled to royalty payments from sales, as well as possible milestone payments., Jan 15, 2008

  2. New Technology For Cancer Screening Listens For The Signs Of Cancer
    Researchers create an acoustic sensor that can report the presence of small amounts of mesothelin, Sept 18, 2007

  3. Alfacell Updates Status Of ONCONASE(R) Phase III Clinical Program
    Company has planned schedule for the potential completion of the final sections of its ONCONASE rolling NDA submission, Sept 13, 2007

  4. Alfacell's Awkward Wait
    Onconase(®) is in its final phase 3 trial for treatment of patients with unresectable malignant mesothelioma, Sept 13, 2007

  5. Data Affirm Benefit of ALIMTA(®) for Patients With Malignant Pleural Mesothelioma
    Alimta(®)-based regimens support patients with devastating disease, Sept 5, 2007

  6. New diagnostic tool for mesothelioma to be developed
    The test will extract microRNAs from a simple blood draw, April 23, 2007

  7. Potential Preventative Action of Ranpirnase
    ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma, April 18, 2007

  8. The Barbara Ann Karmanos Cancer Institute announces significant scientific findings related to Malignant Mesothelioma
    Pathway for Treatment of Malignant Pleural Mesothelioma, April 17, 2007

  9. Mild Hyperthermia Enhances Antitumor Effects of Ranpirnase
    In vitro studies show hyperthermia enhances the therapeutic effects of Onconase in treatment of mesothelioma, March 22, 2007

  10. Study shows Mesomark effective for monitoring Mesothelioma
    NYU Study Validates Use Of Fujirebio Diagnostics' MESOMARK Test For Monitoring An Asbestos-Linked Cancer , March 10, 2007

  11. FDA Grants Orphan Drug status to Onconase for Mesothelioma
    First-in-Class RNAi Drug in Phase IIIB Confirmatory Trial for Unresectable Malignant Mesothelioma , January 30, 2007

  12. FDA Approves MESOMARK® Assay for the Management of Mesothelioma Patients
    First in-vitro test for mesothelioma will enable doctors to more accurately detect recurrence and monitor treatment of patients, January 25, 2007

  13. Alfacell Corporation Files for U.S. Orphan Drug Designation for Onconase
    Onconase is currently being evaluated in a confirmatory Phase IIIb clinical trial in mesothelioma treatment, December 21, 2006

  14. Additional Data From a Phase I Trial of XL647 in Patients With Advanced Solid Tumors
    Results demonstrate that XL647 is generally well tolerated and shows evidence of antitumor activity, November 9, 2006

  15. New study on the safety, tolerability, pharmacokinetics and preliminary efficacy of INNO-305
    INNOVIVE Pharmaceuticals Begins Enrollment in Phase I Study of INNO-305 Peptide Immunotherapy in AML, MDS, Mesothelioma and Non-Small Cell Lung Cancer, October 27, 2006

  16. More evidence that patients treated with Onconase have greater median survival times than patients treated with doxorubicin alone
    Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients With Mesothelioma, October 24, 2006

  17. Zolinza becomes first approved HDAC inhibitor
    FDA approves Zolinza (vorinostat) for cutaneous T-cell lymphoma. This drug is being investigated in other indications including myeloma, mesothelioma and a variety of other cancers, October 10, 2006

  18. Alimta Researchers Recognized As Heroes Of Chemistry
    Three researchers who led the discovery and development of the first drug approved to treat malignant pleural mesothelioma were named as Heroes of Chemistry by the American Chemical Society, September 11, 2006

  19. Progress on Clinical Development Program for ONCONASE(R) in Malignant Mesothelioma
    Pivotal trial is evaluating the effectiveness of ONCONASE plus doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone, August 31, 2006

  20. FDA tells Eli Lilly that their Alimta brochure is misleading
    Patient manual omits facts and risk information about Alimta's safe and effective use, August 1, 2006

  21. News about onocology product candidate SS1P (renamed CAT-5001)
    Cambridge Antibody Technology to take over development of drug that has shown results in clinical trials in patients with mesothelioma, ovarian and pancreatic cancer, July 28, 2006

  22. New Research Shows Unique Promise of Onconase in the Prevention and Treatment of Mesothelioma
    New research findings show that the elusive molecular mechanism that asbestos uses to provoke lung cancer may have been identified, June 27, 2006

  23. CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for Mesothelioma
    PXD101 is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies, June 20, 2006

  24. Alfacell Provides Update on ONCONASE Phase IIIb Confirmatory Registration Trial; Releases First Interim Analysis Data
    Overall median survival time (MST) favored the ONCONASE + doxorubicin treatment group (12 months) over the doxorubicin group. April 27, 2006

  25. Alfacell Achieves Full Patient Enrollment Milestone for the Onconase Phase IIIb Registration Study in Unresectable Malignant Mesothelioma
    Over 600 UMM patients have been enrolled in the Onconase Unrespectable Malignant Mesothelioma study , February 27, 2006

  26. Scientist Reveals His Hopes for Better Tumour Treatment
    Hilary Calvert believes pemetrexed can be improved to provide longer term survival for some patients , March 3, 2006

  27. Alfacell Drug Trial Ahead of Schedule
    Onconase Clinical Trial Enrollment Expected to Be Ahead of Schedule , January 30, 2006

  28. Alfacell Forms New Thoracic Cancer Advisory Board
    Thoracic Cancer Advisory Board will support development of novel ribonuclease (RNase) therapies for the treatment of diseases such as mesothelioma and non-small cell lung cancer , January 27, 2006

  29. Update on Onconase Clinical Program
    Over 300 patients are now enrolled in the international, confirmatory Phase IIIb trial evaluating ONCONASE® (ranpirnase) as a treatment for unresectable malignant mesothelioma, January 19, 2006

  30. Promising Research in Early Detection of Mesothelioma
    A significantly higher concentration of osteopontin was detected in patients with diagnosed cases of mesothelioma compared to subjects with asbestos exposure, January 10, 2006

  31. Morphotek Announces IND Submission for MORAb-009, a Monoclonal Antibody for the Treatment of Mesothelin-Expressing Cancers
    Company will investigate MORAb-009, a monoclonal antibody targeting mesothelin, January 9, 2006

  32. INNOVIVE Pharmaceuticals Licenses WT1 Peptide Cancer Immunotherapeutic from Memorial Sloan-Kettering Cancer Center
    Vaccine is First WT1 Heteroclitic Peptide Immunotherapeutic to Specifically Target CD4 and CD8 Activation, January, 2006

  33. Gene Drug Gives Mesothelioma Patient Second Chance
    First patient in clinical trial gets a second dose of Biogen Idec's new gene drug, October 28, 2005

  34. Novel therapies for pleural mesothelioma
    Osteopontin reveals the early stages of pleural mesothelioma, October 12, 2005

  35. Thoracic Cancer Patients Find New Reasons for Hope with Alimta(®)
    New data may provide important treatment advances in mesothelioma and lung cancer, July 5, 2005


Older news stories

Breaking mesothelioma news

International news